Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUCY1A1 | Q02108 | 3/20 | 0.62 |
| ▸ | GUCY1B1 | Q02153 | 3/20 | 0.62 |
| ▸ | HPGD | P15428 | 9/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.58 |
| ▸ | MAPT | P10636 | 5/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.55 |
| ▸ | TRPC1 | P48995 | 2/20 | 0.53 |
| ▸ | TRPC3 | Q13507 | 2/20 | 0.53 |
| ▸ | STIM1 | Q13586 | 2/20 | 0.53 |
| ▸ | ORAI1 | Q96D31 | 2/20 | 0.53 |
| ▸ | STIM2 | Q9P246 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3033818 | 0.92 | GUCY1A1 (0.54) | GUCY1A1GUCY1B1HPGDKDM4EALDH1A1 | |
| SCHEMBL20646134 | 0.89 | GUCY1A1 (0.67) | GUCY1A1GUCY1B1HPGDKDM4EALDH1A1 | |
| SCHEMBL3994242 | 0.87 | GUCY1A1 (0.62) | GUCY1A1GUCY1B1HPGDKDM4EALDH1A1 | |
| SCHEMBL2852124 | 0.86 | TRPC1 (0.51) | GUCY1A1GUCY1B1HPGDKDM4EALDH1A1 | |
| SCHEMBL3998143 | 0.85 | MAPT (0.55) | GUCY1A1GUCY1B1HPGDKDM4EALDH1A1 | |
| SCHEMBL15502896 | 0.84 | HTT (0.52) | GUCY1A1GUCY1B1HPGDKDM4EALDH1A1 | |
| SCHEMBL15187958 | 0.83 | KEAP1 (0.50) | GUCY1A1GUCY1B1KDM4EALDH1A1MAPT | |
| SCHEMBL1780944 | 0.83 | GUCY1A1 (0.54) | GUCY1A1GUCY1B1HPGDKDM4EALDH1A1 | |
| SCHEMBL3994680 | 0.83 | GUCY1A1 (0.63) | GUCY1A1GUCY1B1HPGDKDM4EALDH1A1 | |
| SCHEMBL4003597 | 0.83 | GUCY1A1 (0.61) | GUCY1A1GUCY1B1HPGDKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3807266-B1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-25 | — | — | EP | disclosed |
| EP-3807266-B1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-25 | — | — | EP | disclosed |
| CN-112585128-B | Pyrazole derivatives as MALT1 inhibitors | 詹森药业有限公司 | 2023-02-21 | — | — | CN | disclosed |
| US-11040031-B2 | Pyrazole derivatives as MALT1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-06-22 | — | — | US | disclosed |
| US-11040031-B2 | Pyrazole derivatives as MALT1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-06-22 | — | — | US | disclosed |
| CN-112585128-A | Pyrazole derivatives as MALT1 inhibitors | 詹森药业有限公司 | 2021-03-30 | — | — | CN | disclosed |
| US-10550102-B2 | Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators | NOVARTIS AG (CH) | 2020-02-04 | — | — | US | disclosed |
| WO-2019243964-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
| US-10364256-B2 | Biaryl pyrazoles as NRF2 regulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-07-30 | — | — | US | disclosed |
| US-10364256-B2 | Biaryl pyrazoles as NRF2 regulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-07-30 | — | — | US | disclosed |
| US-20130065918-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-03-14 | — | — | US | disclosed |
| WO-2012122340-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-09-13 | — | — | WO | disclosed |
| WO-2012058132-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. (US) | 2012-05-03 | — | — | WO | disclosed |
| US-20110118282-A1 | Soluble Guanylate Cyclase Activators | MERCK SHARP & DOHME LLC | 2011-05-19 | — | — | US | disclosed |
| US-20100216764-A1 | Soluble Guanylate Cyclase Activators | MERCK SHARP & DOHME LLC | 2010-08-26 | — | — | US | disclosed |
| US-20090209556-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. | 2009-08-20 | — | — | US | disclosed |
| WO-2009071504-A1 | 2,6-DISUBSTITUTED PYRIDINES AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071504-A1 | 2,6-DISUBSTITUTED PYRIDINES AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009068652-A1 | 2, 6-DISUBSTITUTED PYRIDINES AND 2, 4-DISUBSTITUTED PYRIMIDINES AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-04 | — | — | WO | disclosed |
| WO-2009068652-A1 | 2, 6-DISUBSTITUTED PYRIDINES AND 2, 4-DISUBSTITUTED PYRIMIDINES AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11040031-B2 | Pyrazole derivatives as MALT1 inhibitors | MALT1, PPP3R1, SQSTM1 | GUCY1A1 2341/4885GUCY1B1 1437/4885HPGD 2446/4885 |
| US-20130065918-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | GUCY1A1, GUCY1A2, GUCY1B1 | GUCY1A1 1/4885GUCY1B1 3/4885HPGD 608/4885 |
| US-10364256-B2 | Biaryl pyrazoles as NRF2 regulators | NFE2L2, KEAP1, NQO1 | GUCY1A1 3128/4885GUCY1B1 1807/4885HPGD 161/4885 |
| US-10550102-B2 | Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators | GUCY1A2, GUCY1A1, PDE3A | GUCY1A1 2/4885GUCY1B1 4/4885HPGD 305/4885 |
| US-20110118282-A1 | Soluble Guanylate Cyclase Activators | GUCY1B1, GUCY1A2, GUCY1A1 | GUCY1A1 3/4885GUCY1B1 1/4885HPGD 805/4885 |
| US-20090209556-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | GUCY1B1, GUCY1A2, GUCY1A1 | GUCY1A1 3/4885GUCY1B1 1/4885HPGD 805/4885 |
| US-20100216764-A1 | Soluble Guanylate Cyclase Activators | GUCY1B1, GUCY1A1, GUCY1A2 | GUCY1A1 2/4885GUCY1B1 1/4885HPGD 872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.